黑料官网

header-logo
Research Group Lab Hall
Pharmacology and Toxicology
Michael Widlansky, MD, MPH

Michael E. Widlansky, MD, MPH

Northwestern Mutual Professor of Cardiovascular Medicine, Department of Medicine and Pharmacology; Director of the Cardiovascular Research Center

Contact Information

Education

MD, University of Michigan, 1999
Learn more about the Michael Widlansky Laboratory

Research Experience

  • Aging
  • Coronary Artery Disease
  • Diabetes Complications
  • Diabetes Mellitus, Type 2
  • endothelial function
  • Endothelium-Dependent Relaxing Factors
  • Exercise
  • Hypertension
  • Hypoglycemia
  • Nitric Oxide

Clinical Expertise

  • Coronary Artery Disease
  • Echocardiography

Methodologies and Techniques

  • arterial tonometry
  • digital pulse amplitude tonometry
  • flow mediate dilation
  • Microbubbles
  • Microscopy, Video
  • Plethysmography
  • Ultrasonography

Leadership Positions

  • Associate Fellowship Director, Cardiovascular Diseases
  • Chair, Human Research Affairs Committee
  • Member, Continuing Medical Education Committee
  • Member, Reserach Affairs Committee
  • Research Director, Division of Cardiovascular Medicine

黑料官网 Program / Core Facilities

  • Human Vascular Translational Reserach Core

Research Interests

The vascular endothelium, once thought to be a thin layer of quiescent cells present only to allow smooth, laminar blood flow has discovered to be a central regulator of vascular homeostasis. Both traditional and novel cardiovascular risk factors have been shown to induce the endothelium to take on a phenotype characterized by inflammation, pro-thrombotic stimuli, and vasoconstriction. This state of endothelial “dysfunction” has been shown to precede the development of atherosclerosis and portend cardiovascular events in both those with and without clinically evident cardiovascular disease. Endothelium-derived nitric oxide (EDNO) has been shown to be a central paracrine hormone in the maintenance of normal endothelial function, and a central characteristic of endothelial dysfunction is a reduction in bioavailable EDNO. Measuring EDNO bioavailability in larger conduit vessels and in the microvasculature in vivo can be accomplished by multiple modalities, including high-resolution vascular ultrasound and venous plethysmography. We employ these methodologies to investigate the pathophysiological mechanisms underlying the development of endothelial dysfunction in humans with a variety of disease states, including coronary artery disease and diabetes. Currently, we are investigating the role of disturbances in mitochondrial homeostasis in the modulation of vascular endothelial function in humans with Type II Diabetes. Many of our studies are small, clinical studies that apply different interventions to humans to assess their effects on vascular endothelial function, based on basic and animal work suggesting potential mechanisms for such a difference. Current protocols along this line include investigating the differential effects on vascular function of metformin and glipizide in Type II Diabetics. Our human vascular research laboratory has been formed to foster collaboration with investigators from other disciplines interested in the impact of vascular function on disease states relevant to their fields of interest. Current collaborative efforts include work with investigators from disciplines including Orthopedics, Dermatology, Geriatrics, Pediatric Endocrinology, and Pediatric Cardiology.

Publications

  • (Do Couto N, Hidde M, Grigoriadis G, Sparapani R, Durand M, Widlansky M, Jankowski C, Berendt M, Canales B, Golus S, Norwood Toro LE, Laud P, Kong A, Hoskins K, Lewandowski D, Phillips SA, Gutterman DD, Kriegel AJ, Beyer KMM, Beyer AM, Stolley M.) Cardiooncology. 2025 Aug 21;11(1):75 PMID: 40841694 PMCID: PMC12369258 SCOPUS ID: 2-s2.0-105014033548 08/22/2025

  • (Liu Y, Pandey R, Qiu Q, Liu P, Xue H, Wang J, Therani B, Ying R, Usa K, Grzybowski M, Yang C, Mishra MK, Greene AS, Cowley AW Jr, Rao S, Geurts AM, Widlansky ME, Liang M.) Nat Commun. 2025 Jul 17;16(1):6577 PMID: 40675959 PMCID: PMC12271514 SCOPUS ID: 2-s2.0-105011067559 07/18/2025

  • (Wolfgram DF, Grassl I, Seigworth C, Widlansky ME, Gao Y.) Hemodial Int. 2025 Jul;29(3):346-353 PMID: 40155364 PMCID: PMC12289419 SCOPUS ID: 2-s2.0-105001140356 03/29/2025

  • (Nishijima Y, Hader SN, Birch EC, Chen Y, Widlansky ME, Beyer AM.) Cardiovasc Res. 2025 May 23;121(5):699-701 PMID: 39943809 SCOPUS ID: 2-s2.0-105006564276 02/13/2025

  • (Ray A, Yang C, Stelloh C, Tutaj M, Liu P, Liu Y, Qiu Q, Auer PL, Lin CW, Widlansky ME, Geurts AM, Cowley AW Jr, Liang M, Kwitek AE, Greene AS, Rao S.) Hypertension. 2025 Mar;82(3):476-488 PMID: 39723540 PMCID: PMC12236357 SCOPUS ID: 2-s2.0-85213707759 12/26/2024

  • (He L, Liu Y, Widlansky ME, Kriegel AJ, Qiu Q, Liang M.) Hypertension. 2025 Feb;82(2):181-184 PMID: 39633557 PMCID: PMC11893092 SCOPUS ID: 2-s2.0-85211732398 12/05/2024

  • (Cai C, Choy JS, He G, Widlansky ME, Kassab GS, Fan L.) Computers in Biology and Medicine. October 2025;197 SCOPUS ID: 2-s2.0-105016314044 10/01/2025

  • (Wilcox T, Widlansky ME, Westhoff J, Wang J, Ying R, Thorgerson A, Roberts ML.) Protein Science. June 2025;34(6) SCOPUS ID: 2-s2.0-105005279729 06/01/2025

  • (Palathinkara M, Aljadah M, Thorgerson A, Dawson AZ, Widlansky ME.) Front Nutr. 2025;12:1495633 PMID: 40093880 PMCID: PMC11906339 SCOPUS ID: 2-s2.0-86000721426 03/17/2025

  • (Liu Y, Pandey R, Qiu Q, Liu P, Xue H, Wang J, Therani B, Ying R, Usa K, Grzybowski M, Yang C, Mishra MK, Greene AS, Cowley AW Jr, Rao S, Geurts AM, Widlansky ME, Liang M.) bioRxiv. 2024 Oct 14 PMID: 39463975 PMCID: PMC11507733 10/28/2024

  • (Aljadah M, Khan N, Beyer AM, Chen Y, Blanker A, Widlansky ME.) JACC Adv. 2024 Aug;3(8):101070 PMID: 39055276 PMCID: PMC11269277 07/26/2024

  • (Aljadah M, Khan N, Beyer AM, Chen Y, Blanker A, Widlansky ME.) Jacc Advances. August 2024;3(8) SCOPUS ID: 2-s2.0-85197318304 08/01/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.